DBU Commercial Intern
About the job
- A bachelor's degree is required, with a major in medicine, pharmacy, or a related field.
- The internship requires at least three working days per week and availability for three months or longer; long-term interns are preferred.
- Demonstrated resilience and ability to work under pressure.
- Strong communication and expression skills.
- A proactive work attitude and ability to work well with a team.
- Strong willingness and ability to learn, and adaptability.
- Learn basic medical knowledge, product knowledge, and industry compliance standards under company policies and compliance guidelines.
- Become familiar with academic communication, professional exchange techniques, and daily business processes through simulated practice and observation; the role does not carry business targets.
- Collect market information through the company management system and other compliant channels, and write related market research reports.
- Prepare arrangements and materials for academic meetings.
- Participate in weekly and monthly team meetings, assist with routine data aggregation and work-progress tracking, and provide other internal operational support.
- Learn and follow company compliance policies, operating standards, and conduct requirements for promotional activities.
- Participate in periodic team training and complete periodic professional knowledge assessments and internship performance evaluations.
- Long-term internship availability is preferred.
- High-performing interns who pass the evaluation may have the opportunity to convert to a permanent role on the frontline medical representative team.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)